Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
… that is independently developing and commercializing innovative RNA medicines for patients who suffer from IRDs. … will allow us to more efficiently turn our scientific innovation into multiple potentially life-changing medicines …